相关实验视频

Updated: Aug 11, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

在小鼠中,STE20型激酶TAOK3的淘汰并不能减弱饮食诱导的NAFLD发展

Ying Xia¹, Emma Andersson¹, Mara Caputo¹

¹Department of Chemistry and Molecular Biology, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.

Molecular medicine (Cambridge, Mass.)

|October 20, 2023

概括

在小鼠中,TAOK3的遗传缺陷并没有防止非酒精性脂肪性肝病 (NAFLD),尽管实验室发现. 相关的激酶可能会在体内补偿TAOK3的损失.

科学领域:

代谢性疾病是一种代谢性疾病.
肝病学肝病学是一种肝病学.
分子生物学分子生物学

背景情况:

非酒精性脂肪肝 (NAFLD) 影响全球25%的成年人,与肥胖有关.
肝细胞脂毒性是NAFLD发展的关键因素.
以前已经证明TAOK3激酶在体外调节脂毒性.

研究的目的:

为了研究TAOK3在NAFLD和肥胖小鼠胰岛素抵抗中的体内作用.
为了确定TAOK3缺乏是否影响高脂肪饮食的代谢后果.

主要方法:

使用了Taok3淘汰赛和野生类型的小鼠,食高脂肪饮食.
评估了全身新陈代谢,肝脏NAFLD进展以及多个器官的脂毒性损伤.
在培养肝细胞中分析了脂质积累和压力,使用TAOK3敲击.

主要成果:

TAOK3 缺乏症并没有改变体重,组成或全身葡萄糖/胰岛素平衡.
在基因型之间,饮食诱导的肝硬化,炎症,纤维化或器官脂毒性没有显著差异.
在实验室中TAOK3倒置抑制了肝细胞中的脂质积累和代谢应激.

结论:

在体内,TAOK3遗传缺陷并不能防止饮食引起的NAFLD或代谢功能障碍.
相关的STE20型激酶的肝脏特异性补偿激活可能解释了体内效应的缺乏.
关于TAOK3在脂毒性中的作用的体外发现并未完全转化为体外肥胖背景.

关键词:

遗传补偿是一种遗传补偿.非酒精性脂肪性肝病是非酒精性脂肪性肝病.非酒精性脂肪性肝炎的疾病.系统性葡萄糖和胰岛素稳态.这就是TAOK3OK的意义.

更多相关视频

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

相关概念视频

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.